Privacy Policy
Signals Blog

Contributors

Categories

Regenerative Medicine Deal Review: April

. Welcome to your deal review for the month of April. There is no update yet on the fate of the Cellular Dynamics International/Fujifilm deal, but it appears that CDI made some effort to solicit offers from alternative bidders. Aduro made headlines, though, closing a...

Update from the Clinic: April

. Welcome to your Update from the Clinic for the month of April. Mesenchymal stem cells took a hit as Athersys’ MultiStem came up short, missing its primary endpoint in a Phase 2 study investigating the cells for ischemic stroke. Juno Therapeutics continues to turn...

ISSCR takes a pre-emptive stand on ethical issues

. Last month, Nature published a comment by Edward Lanphier and colleagues, which foreshadows the publication of a study in which scientists have used new genome editing tools to modify the DNA of human embryos. Author David Cyranoski weighed in, suggesting that...

Regenerative Medicine Deal Review: March

. Welcome to your deal review for the month of March. Cellular Dynamics threw shareholders for a loop after making a seemingly hasty decision to sell the company off to Fujifilm in a $307* million deal. Merck and synthetic biology specialist Intrexon announced a...